Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

Analyst Ratings

Consensus Ratings for Idera Pharmaceuticals (NASDAQ:IDRA) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.50 (280.12% upside)

Analysts' Ratings History for Idera Pharmaceuticals (NASDAQ:IDRA)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016WedbushInitiated CoverageOutperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015JPMorgan Chase & Co.Initiated CoverageOverweight$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.11)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.11)($0.10)$20.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.11)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.11)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.11)($0.12)$0.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.11)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.09)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.11)($0.11)$0.03 million$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2013Q213($0.12)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.11)($0.10)($0.11)
Q2 20161($0.11)($0.11)($0.11)
Q3 20162($0.11)($0.09)($0.10)
Q4 20162($0.10)($0.09)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Idera Pharmaceuticals (NASDAQ:IDRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Idera Pharmaceuticals (NASDAQ:IDRA)
DateHeadline
07/28/16 07:33 AMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Cash Balance At $60.16 Millions - Stocks Daily
07/26/16 07:34 AMHC Stocks Outlines: Idera Pharmaceuticals Inc (NASDAQ:IDRA), StemCells Inc (NASDAQ:STEM) - share market updates (press release)
07/23/16 04:19 PMIs $6 Price Target Attainable For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)? - Investor Newswire
07/22/16 07:31 AMCash And Short-Term Investments For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Was $60.16 - Stocks Daily
07/21/16 04:45 PMEarnings Focus and Crowd Sourced Sentiment Review for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - TGP
07/21/16 04:45 PMIdera Pharmaceuticals Incorporated (NASDAQ:IDRA) Shorted Shares Increased 7.74% After Market Selling - Consumer Eagle
07/21/16 04:45 PMBroker Outlook For Idera Pharmaceuticals, Inc. (IDRA) - Fiscal Standard
07/20/16 07:33 AMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 09:48 AMTrading Performance and Target Watch for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Press Telegraph
07/17/16 04:07 PMShares Moving Down on the Week: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Engelwood Daily
07/17/16 04:07 PMShares Experiencing a Downtrend: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - TGP
07/17/16 04:07 PMStrong Sell Calls For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At 0 - Investor Newswire
07/13/16 07:28 AMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 04:40 PMIdera Pharmaceuticals Inc (NASDAQ:IDRA) Institutional Investors Sentiment - Consumer Eagle
07/10/16 04:11 PMNext Weeks Broker Price Targets For Idera Pharmaceuticals, Inc. (IDRA) - Fiscal Standard
07/09/16 07:58 AMIs $6 Within Reach For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)? - Investor Newswire
07/07/16 04:39 PMIdera Pharmaceuticals Incorporated (NASDAQ:IDRA) Shorted Shares Increased By 2.89% - Press Telegraph
07/07/16 04:39 PMInsiders Increasing Positions in: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Press Telegraph
07/07/16 04:39 PMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Cash And Short-Term Investments In Stands At $60.16 - Stocks Daily
07/05/16 09:11 AMHC Stocks Reports: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Sequenom, Inc. (NASDAQ:SQNM) - share market updates (press release)
07/02/16 07:29 AMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Expected to Reach Highs Of $6 - Investor Newswire
07/02/16 07:29 AMIdera Pharmaceuticals, Inc. Stock Momentum at Critical Inflection Point - CML News
07/01/16 07:21 AMIdera Pharmaceuticals Incorporated (NASDAQ:IDRA) Shorted Shares Increased 2.89% After Market Selling - Engelwood Daily
06/30/16 07:27 AMWatching Stock Volatility for: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Engelwood Daily
06/30/16 07:27 AMIdera Pharmaceuticals, Inc. (IDRA) Updated Price Targets - FTSE News
06/28/16 04:31 PMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 04:34 PMIdera Pharmaceuticals Incorporated (NASDAQ:IDRA) Sellers Increased By 2.89% Their Shorts - Press Telegraph
06/25/16 08:25 AMStrong Sell Calls Recommendations For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At 0 - Investor Newswire
06/23/16 07:29 AMBrokers Issue Average Price Target Of 6.33 On Idera Pharmaceuticals, Inc. (IDRA) - Fiscal Standard
06/20/16 04:23 PMThis Weeks Broker Views For Idera Pharmaceuticals, Inc. (IDRA) - Fiscal Standard
06/19/16 04:09 PMStrong Buy Calls Count For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At 3 - Investor Newswire
06/18/16 08:58 AMStrong Buy Calls Count For Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) At 4 - Investor Newswire
06/17/16 08:07 AMIDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/17/16 07:19 AMIdera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3% - Nasdaq
06/17/16 07:19 AMIdera Pharmaceuticals Inc. (IDRA) Jumps 8.33% on June 16 - Equities.com
06/17/16 03:41 AMIdera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3% -
06/08/16 09:52 AMForget Biogen (BIIB), Buy These 5 Biotech Stocks Instead -
06/07/16 04:39 PMETF’s with exposure to Idera Pharmaceuticals, Inc. : June 7, 2016 -
06/07/16 08:08 AMIdera to Present at Two June Investor Healthcare Conferences - [at noodls] - CAMBRIDGE, Mass. and EXTON, Pa., June 07, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics ...
06/03/16 07:17 AMNotable Moving HC Stocks: Johnson & Johnson (NYSE:JNJ), Idera Pharmaceuticals Inc (NASDAQ:IDRA) - share market updates (press release) - Notable Moving HC Stocks: Johnson & Johnson (NYSE:JNJ), Idera Pharmaceuticals Inc (NASDAQ:IDRA)share market updates (press release)Shares of Johnson & Johnson (NYSE:JNJ) ended Thursday session in green amid volatile trading. The shares closed up +1.63 points or 1.45% at $114.41 with 7.31 million shares getting traded. Post opening the session at $112.87, the shares hit an intraday ...and more »
06/02/16 04:51 PMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Yearly Accrued Expenses At $4.274 Millions - Stocks Daily - Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Yearly Accrued Expenses At $4.274 MillionsStocks DailyFor the year closed 2015-12-31 Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) had beginning cash of $19.971 millions. This figure was $19.971 millions for the three-month period ended 2015-12-31. Cash balance was $60.16 millions for the fiscal closed ...Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Posts Quarterly EPS Of $-0.1057 From Continuing OperationsEnterprise Leaderall 3 news articles »
06/02/16 07:19 AMBuy, Sell Or Hold Rating For Idera Pharmaceuticals, Inc. (IDRA)? - Share Trading News - Buy, Sell Or Hold Rating For Idera Pharmaceuticals, Inc. (IDRA)?Share Trading News01/06/2016 – Wedbush began new coverage on Idera Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 6 price target on the stock. 12/07/2015 – Idera Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at ...and more »
06/01/16 04:51 PMInsiders Are Gradually Buying Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - HNN - Insiders Are Gradually Buying Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)HNNAccording to the latest SEC filings, insiders at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) have increased their position in the stock by 7.48% over the past 6 months. Insiders now own 1.00% of total outstanding shares. There are both legal and illegal ...and more »
06/01/16 07:18 AMIdera Pharmaceuticals Inc. (IDRA) Jumps 6.04% on May 31 - Equities.com - Idera Pharmaceuticals Inc. (IDRA) Jumps 6.04% on May 31Equities.comIdera Pharmaceuticals Inc. (IDRA) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 6.04% to $1.58, representing a gain of $0.09 per share. Some 481,012 shares traded hands on 2,063 trades, compared with an ...and more »
05/31/16 04:45 PMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Quarterly EPS Estimate At $-0.12 - Investor Newswire - Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Quarterly EPS Estimate At $-0.12Investor NewswireFirst Call stated that Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) can touch $5.00 in coming one year. For the next quarter, the per-share earnings target is $-0.12 and for ongoing fiscal at $-0.45. EPS target for next year is $-0.46 versus the mean EPS ...and more »
05/31/16 08:59 AMStock Review and Earnings Check on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - HNN - Stock Review and Earnings Check on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Idera Pharmaceuticals, Inc.and more »
05/26/16 07:14 PMIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Impact Score At 94 - Stocks Daily - Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Impact Score At 94Stocks DailyAlpha One explored various online articles released on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...and more »
05/25/16 06:55 PMInsiders Are Gradually Buying Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Wall Street Hints and News - Insiders Are Gradually Buying Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) have increased their position in the stock by 7.82% over the past 6 months. Insiders now own 1.00% of total outstanding shares. There are both legal and illegal ...and more »
05/25/16 12:30 AMIdera Pharmaceuticals Incorporated (NASDAQ:IDRA) Short Interest Decreased By 7.99% - Wall Street Hints and News - Idera Pharmaceuticals Incorporated (NASDAQ:IDRA) Short Interest Decreased By 7.99%Wall Street Hints and NewsThe short interest to Idera Pharmaceuticals Incorporated's float is 11.62%. The stock increased 4.58% or $0.07 during the last trading session, hitting $1.6. About 482,436 shares traded hands. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has declined 49.37% ...
05/21/16 12:06 AMValuable Price Trends to Observe: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) , Impax Laboratories, Inc. (NASDAQ ... - Street Updates - Valuable Price Trends to Observe: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) , Impax Laboratories, Inc. (NASDAQ ...Street UpdatesIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) diminished -2.74%, closing at $1.42 after floating between $1.40 and $1.48. The company has market capitalization of $172.27M. It has twelve month low of $1.19 and twelve month high of $4.42. The recent traded ...and more »

Social

About Idera Pharmaceuticals

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IDRA
  • CUSIP:
Key Metrics:
  • Previous Close: $1.68
  • 50 Day Moving Average: $1.57
  • 200 Day Moving Average: $1.74
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $207.45M
  • Beta: 2.78
  • Current Year EPS Consensus Estimate: $-0.45 EPS
  • Next Year EPS Consensus Estimate: $-0.49 EPS
Additional Links:
Idera Pharmaceuticals (NASDAQ:IDRA) Chart for Thursday, July, 28, 2016